Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.48 |
| ▸ | SRC | P12931 | 8/20 | 0.48 |
| ▸ | ABL2 | P42684 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025199 | 0.85 | TDP1 (0.40) | SMN1; SMN2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8305831 | 0.84 | EHMT2 (0.44) | ABL1SRCABL2ALDH1A1MAPT | |
| SCHEMBL5027767 | 0.83 | GPR119 (0.45) | SMN1; SMN2NSD2 | |
| SCHEMBL5025184 | 0.81 | SRC (0.50) | ABL1SRCABL2ALDH1A1SIRT6 | |
| SCHEMBL4430393 | 0.81 | KDM4E (0.46) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL30017059 | 0.81 | LMNA (0.48) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL21473658 | 0.81 | LMNA (0.48) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5023831 | 0.80 | ABL1 (0.52) | ABL1SRCABL2KDREGFR | |
| SCHEMBL2773208 | 0.79 | MAPT (0.53) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL8305629 | 0.79 | POLB (0.42) | ABL1SRCABL2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299381-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | US | disclosed |
| WO-2005115145-A2 | QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS | WYETH (US) | 2005-12-08 | — | — | WO | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | ABL1 64/4885SRC 960/4885ABL2 508/4885 |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKB, AURKC | ABL1 188/4885SRC 364/4885ABL2 843/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | ABL1 143/4885SRC 347/4885ABL2 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.